Eli Lilly and Company (NYSE: LLY) delivered a strong performance in its third quarter 2025 financial report, driving revenue growth driven by key products and strategic advancements in its research and development pipeline. The company also revised its full-year outlook, reflecting robust business performance and strategic initiatives. Q3 revenue surged by 54%, reaching $17.6 billion, compared to $11.44 billion in the previous year. This growth was fueled by a strong market demand for products like Mounjaro and Zepbound, resulting in an increase in earnings per share (EPS) to $6.21, compared to $1.07 in Q3 2024. Analysts had anticipated an EPS of $6.02 and revenue of $16.01 billion. 4Q 2025 will see Eli Lilly raise its full-year guidance for the same period to be between $63.0 billion and $63.5 billion, up from its previous estimate of $60.0 billion to $62.0 billion. 2025 EPS was projected to range between $21.80 and $22.50 on a reported basis and $23.00 and $23.70 on a non-GAAP basis, reflecting the strong performance across its portfolio. This outlook is fueled by favorable foreign exchange rates. Eli Lilly also saw an increase in gross margin to 82.9% from 57% in Q3 2024, and marketing, selling, and administrative expenses increased by 31%, driven by promotional efforts for ongoing and future launches. Despite challenges in realized prices (down 10%), the company was able to offset this with product mix adjustments. The company’s strong performance is also reflected in their expanding R&D pipeline, with successful Phase 3 trials and regulatory approvals contributing to positive developments. Eli Lilly has raised its full-year 2025 guidance, expecting a robust financial outlook for the coming year.